For the Inventor, By the Inventor

Enter assignee name

Vancouver, Canada

Qlt Inc.

USPTO Granted Patents = 35

CIPO Patents = 16

EPO Patents = 4

Forward Citations = 373

Loading Chart...

Loading Chart...

70 inventors (with patents filed for the assignee):

H Andrew Strong (7 out of 13 patents)

Julia G Levy (7 out of 46 patents)

Anna M Richter (5 out of 25 patents)

4. Janice North (5 out of 8 patents)

5. David W C Hunt (4 out of 9 patents)

6. Zaihui Zhang (4 out of 50 patents)

7. Timothy Scott Daynard (4 out of 16 patents)

8. Ronald Erwin Boch (4 out of 10 patents)

9. Alan R Rapacki (3 out of 35 patents)

10. Shisen Wang (3 out of 12 patents)

11. Philippe Maria Clotaire Margaron (3 out of 7 patents)

12. Valery Rubinchik (2 out of 12 patents)

13. Gregory B Chopiuk (2 out of 11 patents)

14. Mohammad Azab (2 out of 2 patents)

15. Troy Albert Reaves, Jr (2 out of 2 patents)

35 patents: Sort by Forward Citations

1. 9173856 - Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency (2015-11-03),

2. 8333726 - Lacrimal implants and related methods (2012-12-18),

3. 8210902 - Surface treated implantable articles and related methods (2012-07-03),

4. 8158669 - Method for treating neovascularization (2012-04-17),

5. 8106038 - Method for reducing or preventing PDT related inflammation (2012-01-31),

6. 8034803 - Photodynamic therapy of occult age-related macular degeneration (2011-10-11),

7. 7998497 - Nasolacrimal drainage system implants for drug therapy (2011-08-16),

8. 7922702 - Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device (2011-04-12),

9. 7863429 - Treatment of inflammatory diseases including psoriasis (2011-01-04),

10. 7850981 - Immuno-adjuvant PDT treatment of metastatic tumors (2010-12-14),

11. 7753943 - Reduced fluence rate PDT (2010-07-13),

12. 7678829 - Oculoselective drugs and prodrugs (2010-03-16),

13. 7678775 - ILK inhibitors for the treatment of renal disease (2010-03-16),

14. 7504228 - Integrin linked kinase modulation of monocyte activation (2009-03-17),

15. 7479503 - Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases (2009-01-20),

QLT Inc. is a pharmaceutical company that specializes in the development and commercialization of innovative ocular products. With a focus on ophthalmology, their portfolio includes treatments for various eye conditions, such as Age-related Macular Degeneration (AMD), retinitis pigmentosa, and other retinal diseases. QLT Inc. is dedicated to improving patients' vision and quality of life through cutting-edge research, strategic collaborations, and delivering advanced ophthalmic therapies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

35 Patents

#17 in Vancouver

#364 in Canada

#18,611 in the World

Vancouver, Canada

Qlt Inc.

Forward Citations = 373

70 inventors:

H Andrew Strong (7 out of 13 patents)

Julia G Levy (7 out of 46 patents)

Anna M Richter (5 out of 25 patents)

4. Janice North (5 out of 8 patents)

5. David W C Hunt (4 out of 9 patents)

Please report any incorrect information to support@idiyas.com

Loading…